Compare Heron Therapeutics Inc (HRTX) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while State Street SPDR Bloomberg High Yield Bond ETF trades at $95.95. The key difference: State Street SPDR Bloomberg High Yield Bond ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | JNK | |
|---|---|---|
Market Cap | $91.46M | — |
Sector | Health | Fixed Income |
52-Week High | $1.96 | $98.19 |
52-Week Low | $0.39 | $94.66 |
Enterprise Value | $189.36M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
JNK trades at $95.95, down slightly by 0.03% with a bearish technical outlook from moving averages and oscillators. The ETF shows consistent dividend payments but lacks key financial ratio data for fundamental assessment. Recent news highlights bond market volatility and investor focus on high-yield opportunities amid Federal Reserve uncertainty.
The outlook remains cautious due to technical weakness and macroeconomic pressures from potential rate hikes. Risks include fee erosion over time and sensitivity to interest rate changes, while the current yield may appeal to income-focused investors in a volatile market environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
